CD32 Biomarker Kit for Still's Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Still's disease rely heavily on clinical findings and limited research, lacking systematic biomarkers, which complicates accurate diagnosis and treatment, especially given the involvement of inflammatory cytokines and potential viral or bacterial infections.
Innovation Solution
A biomarker composition and diagnostic kit utilizing the protein CD32, along with a method involving an antibody specifically binding to CD32 and measuring the frequency ratio of granulocytes to lymphocytes, to accurately diagnose Still's disease by comparing expression levels in patient samples to normal controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clinical findings and limited research are used for diagnosis, then diagnosis can be made without systematic biomarkers, but diagnostic accuracy and reliability are reduced
Solution Approach 1:
The invention changes the diagnostic parameters by identifying and measuring specific biomarker proteins (CD11b, CD32, CD64) and cellular ratios (granulocyte-to-lymphocyte ratio) instead of relying on general clinical findings. This parameter transformation enables more reliable and objective diagnosis of Still's disease.
2Measurement precision
If systematic biomarkers are developed for diagnosis, then diagnostic precision is improved, but device complexity and research requirements increase
Solution Approach 1:
The invention segments the diagnostic approach by focusing on specific measurable parameters (individual protein expression levels of CD11b, CD32, CD64 and the granulocyte-to-lymphocyte ratio) rather than attempting to measure all possible inflammatory markers. This segmentation makes the diagnostic system more manageable and clinically feasible while maintaining high precision.
3Reliability
If treatment depends on experience without consensus, then treatment can be provided immediately, but treatment effectiveness and patient outcomes are compromised
Solution Approach 1:
The invention establishes a feedback mechanism by using biomarker measurements (CD11b, CD32, CD64 expression levels and granulocyte-to-lymphocyte ratio) to objectively assess disease status and monitor treatment response. This feedback loop enables evidence-based treatment adjustments rather than relying solely on clinical experience.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for precise diagnosis of Still's disease in both children and adults, enhancing therapeutic outcomes by identifying specific biomarkers and cellular ratios indicative of the condition.
Implementation Method 1
an antibody specifically binding to a CD32 cell-surface antigen
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention relates to a biomarker composition for diagnosing Still's disease, a diagnostic kit, and a diagnostic method, and more particularly, the present invention can accurately diagnose Still's disease in children and adults using the expression level of CD11b or CD32 and the frequency of granulocytes to lymphocytes as indexes.